Literature DB >> 26546496

De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease.

Konstantinos Papamichael1, Pantelis Karatzas1, Gerasimos J Mantzaris2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26546496      PMCID： PMC4957471          DOI： 10.1093/ecco-jcc/jjv206

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  5 in total

1.  Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease.

Authors:  S Paul; X Roblin; L Peyrin-Biroulet
Journal:  Aliment Pharmacol Ther       Date:  2015-10       Impact factor: 8.171

2.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Authors:  Niels Vande Casteele; Marc Ferrante; Gert Van Assche; Vera Ballet; Griet Compernolle; Kristel Van Steen; Steven Simoens; Paul Rutgeerts; Ann Gils; Séverine Vermeire
Journal:  Gastroenterology       Date:  2015-02-24       Impact factor: 22.682

Review 3.  Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.

Authors:  B Pariente; D Laharie
Journal:  Aliment Pharmacol Ther       Date:  2014-06-23       Impact factor: 8.171

4.  Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?

Authors:  Pauliina Molander; Martti Färkkilä; Ari Ristimäki; Kimmo Salminen; Helena Kemppainen; Timo Blomster; Ritva Koskela; Airi Jussila; Henna Rautiainen; Markku Nissinen; Johanna Haapamäki; Perttu Arkkila; Urpo Nieminen; Juha Kuisma; Jari Punkkinen; Kaija-Leena Kolho; Harri Mustonen; Taina Sipponen
Journal:  J Crohns Colitis       Date:  2015-01       Impact factor: 9.071

5.  Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.

Authors:  Vivian W Huang; Connie Prosser; Karen I Kroeker; Haili Wang; Carol Shalapay; Neil Dhami; Darryl K Fedorak; Brendan Halloran; Levinus A Dieleman; Karen J Goodman; Richard N Fedorak
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325
  5 in total
  5 in total

1.  Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.

Authors:  Anthony Buisson; Wing Yan Mak; Michael J Andersen; Donald Lei; Stacy A Kahn; Joel Pekow; Russel D Cohen; Nada Zmeter; Bruno Pereira; David T Rubin
Journal:  J Crohns Colitis       Date:  2019-08-14       Impact factor: 9.071

2.  Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.

Authors:  Fernando Magro; Joana Afonso; Susana Lopes; Rosa Coelho; Raquel Gonçalves; Paulo Caldeira; Paula Lago; Helena Tavares de Sousa; Jaime Ramos; Ana Rita Gonçalves; Paula Ministro; Isadora Rosa; Ana Isabel Vieira; Patrícia Andrade; João-Bruno Soares; Diana Carvalho; Paula Sousa; Tânia Meira; Joanne Lopes; Joana Moleiro; Cláudia Camila Dias; Amílcar Falcão; Karel Geboes; Fatima Carneiro
Journal:  EBioMedicine       Date:  2017-06-07       Impact factor: 8.143

3.  Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial.

Authors:  Marleen Bouhuys; Willem S Lexmond; Gerard Dijkstra; Triana Lobatón; Edouard Louis; Stephanie van Biervliet; Henk Groen; Jordi Guardiola; Patrick van Rheenen
Journal:  BMJ Open       Date:  2021-11-03       Impact factor: 2.692

Review 4.  Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.

Authors:  Laurent Peyrin-Biroulet; William J Sandborn; Remo Panaccione; Eugeni Domènech; Lieven Pouillon; Britta Siegmund; Silvio Danese; Subrata Ghosh
Journal:  Therap Adv Gastroenterol       Date:  2021-12-09       Impact factor: 4.409

5.  [Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers].

Authors: 
Journal:  Z Gastroenterol       Date:  2020-07-13       Impact factor: 2.000
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.